Direct Effects of Phosphate on Vascular Cell Function

Advances in Chronic Kidney Disease

Volumn 18, Issue 2, 2011, Pages 105-112

  Lau, Wei Ling ^a   Pai, Ashwini ^a   Moe, Sharon M ^a   Giachelli, Cecilia M ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b University of Washington   (United States)

Author keywords

Chronic kidney disease; Elastin degradation; Phosphate; Smooth muscle cell; Vascular calcification

Indexed keywords

PHOSPHATE;

AORTA VALVE; APOPTOSIS; BLOOD VESSEL CALCIFICATION; BLOOD VESSEL WALL; CELL FUNCTION; EXTRACELLULAR MATRIX; HUMAN; HYPERPHOSPHATEMIA; NONHUMAN; PHENOTYPE; PHOSPHATE TRANSPORT; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER;

APOPTOSIS; CALCINOSIS; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HUMANS; HYPERPHOSPHATEMIA; MUSCLE, SMOOTH, VASCULAR; PHENOTYPE; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE III;

EID: 79952613184     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.12.002     Document Type: Review

References (88)

1. Edmonds M., Morrison N., Laws J., Watkins P. Medial arterial calcification and diabetic neuropathy. Br Med J (Clin Res Ed) 1982, 284:928-930.
2. Giachelli C. The emerging role of phosphate in vascular calcification. Kidney Int 2009, 75:890-897.
3. Goodman W., London G., Amann K., et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004, 43:572-579.
4. London G., Guérin A., Marchais S., Métivier F., Pannier B., Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003, 18:1731-1740.
5. Guerin A., Blacher J., Pannier B., Marchais S., Safar M., London G. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001, 103:987-992.
6. Vanholder R., Massy Z., Argiles A., Spasovski G., Verbeke F., Lameire N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005, 20:1048-1056.
7. Ahmed S., O'Neill K., Hood A., Evan A., Moe S. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001, 37:1267-1276.
8. Shao J., Cai J., Towler D. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol 2006, 26:1423-1430.
9. Otto C., Lind B., Kitzman D., Gersh B., Siscovick D. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999, 341:142-147.
10. Umana E., Ahmed W., Alpert M. Valvular and perivalvular abnormalities in end-stage renal disease. Am J Med Sci 2003, 325:237-242.
11. Block G., Hulbert-Shearon T., Levin N., Port F. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998, 31:607-617.
12. Young E., Albert J., Satayathum S., et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005, 67:1179-1187.
13. Dhingra R., Sullivan L., Fox C., et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007, 167:879-885.
14. Noordzij M., Korevaar J., Bos W., et al. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients. Nephrol Dial Transplant 2006, 21:2513-2520.
15. Tentori F., Blayney M., Albert J., et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008, 52:519-530.
16. Block G., Klassen P., Lazarus J., Ofsthun N., Lowrie E., Chertow G. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15:2208-2218.
17. Chertow G., Burke S., Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002, 62:245-252.
18. Block G., Raggi P., Bellasi A., Kooienga L., Spiegel D. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007, 71:438-441.
19. Russo D., Miranda I., Ruocco C., et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007, 72:1255-1261.
20. Qunibi W., Moustafa M., Muenz L., et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008, 51:952-965.
21. Kestenbaum B., Sampson J., Rudser K., et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005, 16:520-528.
22. Tonelli M., Sacks F., Pfeffer M., Gao Z., Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005, 112:2627-2633.
23. Hruska K., Mathew S., Lund R., Qiu P., Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008, 74:148-157.
24. Levin A., Bakris G., Molitch M., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007, 71:31-38.
25. Farzaneh-Far A., Shanahan C. Biology of vascular calcification in renal disease. Nephron Exp Nephrol 2005, 101:e134-e138.
26. O'Neill W. The fallacy of the calcium-phosphorus product. Kidney Int 2007, 72:792-796.
27. Shanahan C., Weissberg P., Metcalfe J. Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells. Circ Res 1993, 73:193-204.
28. Jono S., McKee M., Murry C., et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000, 87:E10-E17.
29. Block G. Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients. Clin Nephrol 2000, 54:318-324.
30. Steitz S., Speer M., Curinga G., et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001, 89:1147-1154.
31. Lomashvili K., Garg P., O'Neill W. Chemical and hormonal determinants of vascular calcification in vitro. Kidney Int 2006, 69:1464-1470.
32. Lomashvili K., Cobbs S., Hennigar R., Hardcastle K., O'Neill W. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol 2004, 15:1392-1401.
33. Wada T., McKee M., Steitz S., Giachelli C. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999, 84:166-178.
34. El-Abbadi M., Pai A., Leaf E., et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int 2009, 75:1297-1307.
35. Graciolli F., Neves K., dos Reis L., et al. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Nephrol Dial Transplant 2009, 24:1416-1421.
36. Speer M., Yang H., Brabb T., et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 2009, 104:733-741.
37. Shroff R., McNair R., Figg N., et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008, 118:1748-1757.
38. Kaden J., Bickelhaupt S., Grobholz R., et al. Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis 2004, 13:560-566.
39. Tyson K., Reynolds J., McNair R., Zhang Q., Weissberg P., Shanahan C. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003, 23:489-494.
40. Moe S., Duan D., Doehle B., O'Neill K., Chen N. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 2003, 63:1003-1011.
41. Schlieper G., Aretz A., Verberckmoes S., et al. Ultrastructural analysis of vascular calcifications in uremia. J Am Soc Nephrol 2010, 21:689-696.
42. Román-García P., Carrillo-López N., Fernández-Martín J., Naves-Díaz M., Ruiz-Torres M., Cannata-Andía J. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 2010, 46:121-128.
43. Takeda E., Taketani Y., Morita K., Miyamoto K. Sodium-dependent phosphate co-transporters. Int J Biochem Cell Biol 1999, 31:377-381.
44. Werner A., Dehmelt L., Nalbant P. Na+-dependent phosphate cotransporters: the NaPi protein families. J Exp Biol 1998, 201:3135-3142.
45. Boyer C., Baines A., Beaulieu E., Béliveau R. Immunodetection of a type III sodium-dependent phosphate cotransporter in tissues and OK cells. Biochim Biophys Acta 1998, 1368:73-83.
46. Kavanaugh M., Miller D., Zhang W., et al. Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci U S A 1994, 91:7071-7075.
47. Sugitani H., Wachi H., Murata H., Sato F., Mecham R., Seyama Y. Characterization of an in vitro model of calcification in retinal pigmented epithelial cells. J Atheroscler Thromb 2003, 10:48-56.
48. Chen N., O'Neill K., Duan D., Moe S. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002, 62:1724-1731.
49. Li X., Yang H., Giachelli C. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006, 98:905-912.
50. Villa-Bellosta R., Bogaert Y., Levi M., Sorribas V. Characterization of phosphate transport in rat vascular smooth muscle cells: implications for vascular calcification. Arterioscler Thromb Vasc Biol 2007, 27:1030-1036.
51. Williams G., Sallis J. Structure-activity relationship of inhibitors of hydroxyapatite formation. Biochem J 1979, 184:181-184.
52. Fleisch H., Russell R., Bisaz S., Mühlbauer R., Williams D. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1970, 1:12-18.
53. Villa-Bellosta R., Sorribas V. Phosphonoformic acid prevents vascular smooth muscle cell calcification by inhibiting calcium-phosphate deposition. Arterioscler Thromb Vasc Biol 2009, 29:761-766.
54. Villa-Bellosta R., Levi M., Sorribas V. Vascular smooth muscle cell calcification and SLC20 inorganic phosphate transporters: effects of PDGF, TNF-alpha, and Pi. Pflugers Arch 2009, 458:1151-1161.
55. Festing M., Speer M., Yang H., Giachelli C. Generation of mouse conditional and null alleles of the type III sodium-dependent phosphate cotransporter PiT-1. Genesis 2009, 47:858-863.
56. Li X., Yang H., Giachelli C. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 2008, 199:271-277.
57. Chen N., Duan D., O'Neill K., et al. The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells. Kidney Int 2006, 70:1046-1053.
58. Mathew S., Tustison K., Sugatani T., Chaudhary L., Rifas L., Hruska K. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 2008, 19:1092-1105.
59. Johnson K., Polewski M., Terkeltaub R. Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells. Circ Res 2008, 102:529-537.
60. Lorand L., Graham R. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003, 4:140-156.
61. Prosdocimo D., Wyler S., Romani A., O'Neill W., Dubyak G. Regulation of vascular smooth muscle cell calcification by extracellular pyrophosphate homeostasis: synergistic modulation by cyclic AMP and hyperphosphatemia. Am J Physiol Cell Physiol 2010, 298:C702-C713.
62. Huang M., Sage A., Lu J., Demer L., Tintut Y. Phosphate and pyrophosphate mediate PKA-induced vascular cell calcification. Biochem Biophys Res Commun 2008, 374:553-558.
63. Moe S., Chen N. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008, 19:213-216.
64. Ketteler M. Fetuin-A and extraosseous calcification in uremia. Curr Opin Nephrol Hypertens 2005, 14:337-342.
65. Silverstein D. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol 2009, 24:1445-1452.
66. Tanikawa T., Okada Y., Tanikawa R., Tanaka Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res 2009, 46:572-580.
67. Reynolds J., Joannides A., Skepper J., et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004, 15:2857-2867.
68. Shroff R., McNair R., Skepper J., et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 2010, 21:103-112.
69. Son B., Kozaki K., Iijima K., et al. Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circ Res 2006, 98:1024-1031.
70. Collett G., Wood A., Alexander M., et al. Receptor tyrosine kinase Axl modulates the osteogenic differentiation of pericytes. Circ Res 2003, 92:1123-1129.
71. Son B., Kozaki K., Iijima K., et al. Gas6/Axl-PI3K/Akt pathway plays a central role in the effect of statins on inorganic phosphate-induced calcification of vascular smooth muscle cells. Eur J Pharmacol 2007, 556:1-8.
72. Ewence A., Bootman M., Roderick H., et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res 2008, 103:e28-e34.
73. Sage A, Lu J, Tintut Y, Demer L. Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int. In press.
74. Bertipaglia B., Ortolani F., Petrelli L., et al. Cell characterization of porcine aortic valve and decellularized leaflets repopulated with aortic valve interstitial cells: the VESALIO Project (Vitalitate Exornatum Succedaneum Aorticum Labore Ingenioso Obtenibitur). Ann Thorac Surg 2003, 75:1274-1282.
75. Mathieu P., Voisine P., Pépin A., Shetty R., Savard N., Dagenais F. Calcification of human valve interstitial cells is dependent on alkaline phosphatase activity. J Heart Valve Dis 2005, 14:353-357.
76. Rattazzi M., Iop L., Faggin E., et al. Clones of interstitial cells from bovine aortic valve exhibit different calcifying potential when exposed to endotoxin and phosphate. Arterioscler Thromb Vasc Biol 2008, 28:2165-2172.
77. Mohler Er, Chawla M., Chang A., et al. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 1999, 8:254-260.
78. Niederhoffer N., Lartaud-Idjouadiene I., Giummelly P., Duvivier C., Peslin R., Atkinson J. Calcification of medial elastic fibers and aortic elasticity. Hypertension 1997, 29:999-1006.
79. Bobryshev Y., Lord R., Warren B. Calcified deposit formation in intimal thickenings of the human aorta. Atherosclerosis 1995, 118:9-21.
80. Hosaka N., Mizobuchi M., Ogata H., et al. Elastin degradation accelerates phosphate-induced mineralization of vascular smooth muscle cells. Calcif Tissue Int 2009, 85:523-529.
81. Bouvet C., Moreau S., Blanchette J., de Blois D., Moreau P. Sequential activation of matrix metalloproteinase 9 and transforming growth factor beta in arterial elastocalcinosis. Arterioscler Thromb Vasc Biol 2008, 28:856-862.
82. Rucker R. Calcium binding to elastin. Adv Exp Med Biol 1974, 48:185-209.
83. Simionescu A., Philips K., Vyavahare N. Elastin-derived peptides and TGF-beta1 induce osteogenic responses in smooth muscle cells. Biochem Biophys Res Commun 2005, 334:524-532.
84. Heldin C., Miyazono K., ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390:465-471.
85. Lee K., Kim H., Li Q., et al. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000, 20:8783-8792.
86. Navaneethan S., Palmer S., Craig J., Elder G., Strippoli G. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009, 54:619-637.
87. Tonelli M., Pannu N., Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010, 362:1312-1324.
88. Kapustin A., Shanahan C. Targeting vascular calcification: softening-up a hard target. Curr Opin Pharmacol 2009, 9:84-89.